HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $180 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $180.
August 28, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioNTech's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $180.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $180 indicates the firm's continued confidence in BioNTech's performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100